Detalles de la búsqueda
1.
A cost-consequence analysis of the Xpert Xpress CoV-2/Flu/RSV plus test strategy for the diagnosis of influenza-like illnesses.
J Med Econ
; 27(1): 430-441, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38328858
2.
Bleeding in patients with hemophilia who have inhibitors: Modeling US medical system utilization and cost avoidance between recombinant factor VIIa products with different clinical dosing requirements.
J Manag Care Spec Pharm
; 28(5): 518-527, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35343812
3.
Health Economics of Selective Early Rescue Surfactant Administration and Standard Surfactant Administration for Newborns With Respiratory Distress Syndrome.
J Pediatr Pharmacol Ther
; 27(8): 695-702, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36415764
4.
Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective.
Am J Cardiovasc Drugs
; 22(1): 93-104, 2022 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-34331235
5.
The impact of increasing multitarget stool DNA use among colorectal cancer screeners in a self-insured US employer population.
J Mark Access Health Policy
; 9(1): 1948670, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34512929
6.
The health economic impact of varying levels of adherence to colorectal screening on providers and payers.
J Med Econ
; 24(1): 69-78, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33970747
7.
An updated cost-utility model for onasemnogene abeparvovec (Zolgensma®) in spinal muscular atrophy type 1 patients and comparison with evaluation by the Institute for Clinical and Effectiveness Review (ICER).
J Mark Access Health Policy
; 9(1): 1889841, 2021 Feb 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-33708361
8.
Cost-consequence analysis of 18F-fluciclovine for the staging of recurrent prostate cancer.
J Mark Access Health Policy
; 8(1): 1749362, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32341772
9.
Projecting total costs and health consequences of increasing mt-sDNA utilization for colorectal cancer screening from the payer and integrated delivery network perspectives.
J Med Econ
; 23(6): 581-592, 2020 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-32063100
10.
Cost-effectiveness analysis of using onasemnogene abeparvocec (AVXS-101) in spinal muscular atrophy type 1 patients.
J Mark Access Health Policy
; 7(1): 1601484, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31105909
11.
Budget Impact Analysis of Using Daunorubicin-Cytarabine Liposome in Patients with Newly Diagnosed Therapy-Related AML or AML and Myelodysplasia-Related Changes.
Am Health Drug Benefits
; 11(7): 380-386, 2018 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-30647825
12.
Evaluating cost benefits of combination therapies for advanced melanoma.
Drugs Context
; 5: 212297, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27540409
13.
Use of Oritavancin in Moderate-to-Severe ABSSSI Patients Requiring IV Antibiotics: A U.S. Payer Budget Impact Analysis.
J Manag Care Spec Pharm
; 22(6): 752-64, 2016 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-27231802
14.
Use of Oritavancin in Acute Bacterial Skin and Skin Structure Infections Patients Receiving Intravenous Antibiotics: A US Hospital Budget Impact Analysis.
Clin Drug Investig
; 36(2): 157-68, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26692006
Resultados
1 -
14
de 14
1
Próxima >
>>